← Therapeutics
Details checkedClinical trial listing onlyCheckedtrial
EHT102 by EuHearing
Also known as: EHT102, EHT102 Injection
Shanghai EuHearing Therapeutics Co., Ltd
Company
Shanghai EuHearing Therapeutics Co., Ltd
Program Type
Therapeutic
Modality
Gene Therapy
Stage
Phase 1/2
Status
Active
Target Gene
OTOF
Route / Mode
Otic gene therapy injection; exact surgical route not normalized in this pass
Confidence
90%
Status Confidence
Status needs checking
Evidence Strength
Needs more support
Last Reviewed
2026-06-08
Geography
China
Population
pediatric, genetic, congenital, otof-dfnb9, bilateral
Trial IDs
1
Mechanism
Investigational OTOF gene therapy for congenital hearing loss caused by biallelic otoferlin mutations.
Indications
Notes
Verified active Phase 1/2 trial-derived OTOF gene therapy record. The registry describes EHT102 injection in pediatric patients with congenital hearing loss secondary to biallelic hOTOF mutations.
Evidence & Sources
1 structured sourcesclinicaltrials
Supports: canonicalName, aliases, company, stage, status, targetGene, indications, populationTags...
IDs: NCT07288580, EHT102, OTOF
Key Events
Clinical Trials (1)
Data Checks
route-specifics-need-surgical-source
Related Programs
Otarmeni by Regeneron
Company: Regeneron Pharmaceuticals · Gene Therapy · Approved
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
AK-OTOF by Eli Lilly and Akouos
Company: Eli Lilly and Company · Gene Therapy · Phase 2
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
SENS-501 by Sensorion
Company: Sensorion · Gene Therapy · Phase 1/2
Rincell-1 by Rinri Therapeutics
Company: Rinri Therapeutics · Cell Therapy · Phase 1/2